Articles from Beta Bionics, Inc.

IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr. Michel is Chief Executive Officer of Delcath Systems (Nasdaq: DCTH), a commercial-stage interventional oncology company.

IRVINE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter and year ended December 31, 2024 and introduced its annual guidance for the year ending December 31, 2025.

IRVINE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2024 financial results after the financial markets close on Tuesday, March 25, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company’s fourth quarter and full year 2024 performance.

IRVINE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the closing of its upsized initial public offering of 13,800,000 shares of common stock, including the full exercise of the underwriters’ option to purchase 1,800,000 additional shares, consisting of 475,000 additional shares from Beta Bionics and 1,325,000 shares from the selling stockholders named in the prospectus, at a price to the public of $17.00 per share. The gross proceeds to Beta Bionics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Beta Bionics, were approximately $212.1 million. Beta Bionics did not receive any proceeds from any sale of shares by the selling stockholders. The shares began trading on the Nasdaq Global Market on January 30, 2025 under the ticker symbol “BBNX.”

IRVINE, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, today announced the pricing of its upsized initial public offering of 12,000,000 shares of common stock at a price to the public of $17.00 per share. The gross proceeds to Beta Bionics from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Beta Bionics, are expected to be $204.0 million. In addition, the underwriters have a 30-day option to purchase up to an additional 1,800,000 shares of common stock at the public offering price, less underwriting discounts and commissions, consisting of 475,000 shares from Beta Bionics and 1,325,000 shares from the selling stockholders named in the prospectus. Beta Bionics will not receive any proceeds from any sale of shares by the selling stockholders.

IRVINE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Beta Bionics has applied to list its common stock on the Nasdaq Global Market under the ticker symbol “BBNX.”